| Target Price | $13.26 |
| Price | $13.03 |
| Potential |
1.77%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Oscar Health 2026 .
The average Oscar Health target price is $13.26.
This is
1.77%
register free of charge
$20.95
60.76%
register free of charge
$8.08
37.99%
register free of charge
|
|
| A rating was issued by 16 analysts: 2 Analysts recommend Oscar Health to buy, 6 to hold and 8 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Oscar Health stock has an average upside potential 2026 of
1.77%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 9.18 | 12.28 |
| 56.54% | 33.80% | |
| EBITDA Margin | 0.97% | -1.55% |
| 127.87% | 259.10% | |
| Net Margin | 0.28% | -3.12% |
| 106.00% | 1,225.99% |
12 Analysts have issued a sales forecast Oscar Health 2025 . The average Oscar Health sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Oscar Health EBITDA forecast 2025. The average Oscar Health EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Oscar Health Analysts have issued a net profit forecast 2025. The average Oscar Health net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.10 | -1.47 |
| 108.20% | 1,570.00% | |
| P/E | negative | |
| EV/Sales | 0.18 |
13 Analysts have issued a Oscar Health forecast for earnings per share. The average Oscar Health EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 14 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 07 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Jul 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 14 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 07 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Jul 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


